RxDoctor Payments Data

Muhammad Tariq, MD

Interventional Cardiology · Greenville, NCNPI 1124374939

Payments from drug & device makers

$16,040in general payments, 2019–2025

Across 242 payments — averaging $66.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Inari Medical, Inc.$9K
  • Abiomed$2K
  • Boston Scientific$1K
  • Abbott$978
  • E.r. Squibb & Sons, L.L.C.$495
  • Recor Medical Inc$392
  • plus $3K from 24 others

What the payments were for

  • Speaking & faculty fees$4,75030%
  • Travel & lodging$3,38521%
  • Food & beverage$7,76048%
  • Education$1441%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,040 in reported general payments places this provider in the 55th percentile of 180 interventional cardiology providers in North Carolina.

See all interventional cardiology providers in North Carolina

Medicare billing

Part B allowed, 2024
$247,441
Medicare patients
1,669
Services billed
3,085

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban125$105,885
Repatha SureclickEvolocumab157$103,248
EntrestoSacubitril/Valsartan42$44,450
XareltoRivaroxaban41$25,141
BrilintaTicagrelor37$19,934
FarxigaDapagliflozin Propanediol18$13,104
VascepaIcosapent Ethyl14$6,508
Ranolazine ErRanolazine73$5,048
Isosorbide Mononitrate ErIsosorbide Mononitrate207$2,774
Metoprolol Succinate277$2,581
Atorvastatin Calcium189$1,579
ClopidogrelClopidogrel Bisulfate127$1,285
Midodrine Hcl23$1,043
Amlodipine Besylate175$950
Rosuvastatin Calcium103$829

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$127$105,885125 claims
NovartisEntresto$352$44,45042 claims
AstraZenecaBrilinta, Farxiga$49$33,03855 claims
Johnson & JohnsonXarelto$124$25,14141 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 180 interventional cardiology providers in North Carolina.

Other interventional cardiology in Greenville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →